Trials / Conditions / Hemorrhagic Fever, Ebola

Hemorrhagic Fever, Ebola

11 registered clinical trials studyying Hemorrhagic Fever, Ebola.

Status	Trial	Sponsor	Phase
Completed	Ad26.ZEBOV, MVA-BN-Filo Vaccination in Children and Adults Previously Vaccinated With Control in the EBOVAC-Sa NCT05284097	London School of Hygiene and Tropical Medicine	Phase 2
Completed	Open Study of the Duration of Immunity After Vaccination With GamEvac NCT02911428	Gamaleya Research Institute of Epidemiology and Microbiology, Health Ministry of the Russian Federation	—
Terminated	Long-term Safety Follow-up of Participants Exposed to the Candidate Ebola Vaccines Ad26.ZEBOV and/or MVA-BN-Fi NCT02661464	Janssen Vaccines & Prevention B.V.	Phase 3
Completed	Safety, Tolerability and Immunogenicity Study of 2-dose Heterologous Regimens for Ebola Vaccines Ad26.ZEBOV/MV NCT02598388	Janssen Vaccines & Prevention B.V.	Phase 2
Completed	Safety, Tolerability and Immunogenicity Study of 3 Prime-boost Regimens for Ebola Vaccines Ad26.ZEBOV/MVA-BN-F NCT02564523	Janssen Vaccines & Prevention B.V.	Phase 2
Completed	Evaluating the Safety of and Immune Response to a Human Parainfluenza Virus Type 3 Ebola Virus Vaccine (HPIV3- NCT02564575	National Institute of Allergy and Infectious Diseases (NIAID)	Phase 1
Completed	STRIVE (Sierra Leone Trial to Introduce a Vaccine Against Ebola) NCT02378753	Centers for Disease Control and Prevention	Phase 2 / Phase 3
Completed	Emergency Evaluation of Convalescent Plasma for Ebola Viral Disease (EVD) in Guinea NCT02342171	Institute of Tropical Medicine, Belgium	Phase 2 / Phase 3
Completed	Clinical Trial of Ebola Vaccines cAd3-EBO, cAd3-EBOZ and MVA-EbolaZ in Healthy Adults in Uganda NCT02354404	National Institute of Allergy and Infectious Diseases (NIAID)	Phase 1
Completed	Phase I Trial to Assess the Safety, Tolerability and Immunogenicity of a Ebola Virus Vaccine (rVSVΔG-ZEBOV-GP) NCT02283099	Universitätsklinikum Hamburg-Eppendorf	Phase 1
Completed	Experimental Ebola Vaccine Trial NCT00072605	National Institute of Allergy and Infectious Diseases (NIAID)	Phase 1